文献速递甲状腺疾病

仑伐替尼联合帕博利珠单抗治疗未分化及低分化甲状腺癌有效

Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma.
PubMed 文献 · Thyroid · 2021-04-15

回顾性分析6例转移性未分化甲状腺癌(ATC)和2例低分化甲状腺癌(PDTC)患者,接受仑伐替尼联合帕博利珠单抗治疗。ATC最佳总体缓解率为66%完全缓解(4/6),PDTC为2/2部分缓解。中位无进展生存期17.75个月,中位总生存期18.5个月,4/8例发生III/IV级毒性需减量或停药。

要点

  • 联合方案在ATC中完全缓解率达66%(4/6),PDTC中2/2部分缓解。
  • 中位PFS 17.75个月,中位OS 18.5个月,3例ATC长期无复发。
  • 4/8例出现III/IV级毒性,需调整仑伐替尼剂量。

核心结论

  • 仑伐替尼联合帕博利珠单抗可能对ATC/PDTC安全有效,可实现完全和长期缓解。

研究设计与样本

  • 回顾性研究,纳入6例转移性ATC和2例PDTC患者。
  • 仑伐替尼起始剂量14-24 mg每日,联合帕博利珠单抗200 mg每三周固定剂量。
  • 肿瘤行全外显子组测序和PD-L1表达检测(TPS 1-90%)。

主要发现

  • ATC最佳总体缓解:66%完全缓解(4/6),16%疾病稳定(1/6),16%疾病进展(1/6)。
  • PDTC最佳总体缓解:2/2部分缓解。
  • 所有患者中位无进展生存期17.75个月,ATC中位16.5个月,治疗持续时间1至40个月。
  • 中位总生存期18.5个月,3例ATC患者无复发存活(40、27、19个月)。
  • 4/8例发生III/IV级毒性,需减量或停用仑伐替尼。

关键数值与推荐

  • 长期(>2年)或完全缓解的患者均具有TMB升高或PD-L1 TPS>50%。

临床怎么用

  • 联合方案可作为ATC/PDTC的治疗选择,尤其对TMB升高或PD-L1 TPS>50%者。
  • 需密切监测III/IV级毒性并及时调整仑伐替尼剂量。
  • 该方案正在II期临床试验(ATLEP)中系统评估。

局限性

  • 回顾性研究,样本量小(共8例)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Anaplastic thyroid carcinoma (ATC) and metastatic poorly differentiated thyroid carcinomas (PDTCs) are rare aggressive malignancies with poor overall survival (OS) despite extensive multimodal therapy. These tumors are highly proliferative, with frequently increased tumor mutational burden (TMB) compared with differentiated thyroid carcinomas, and elevated programmed death ligand 1 (PD-L1) levels. These tumor properties implicate responsiveness to antiangiogenic and antiproliferative multikinase inhibitors such as lenvatinib, and immune checkpoint inhibitors such as pembrolizumab. Patients and Methods: In a retrospective study, we analyzed six patients with metastatic ATC and two patients with PDTC, who received a combination therapy of lenvatinib and pembrolizumab. Lenvatinib was started at 14-24 mg daily and combined with pembrolizumab at a fixed dose of 200 mg every three weeks. Maximum treatment duration with this combination was 40 months, and 3 of 6 ATC patients are still on therapy. Patient tumors were characterized by whole-exome sequencing and PD-L1 expression levels (tumor proportion score [TPS] 1-90%). Results: Best overall response (BOR) within ATCs was 66% complete remissions (4/6 CR), 16% stable disease (1/6 SD), and 16% progressive disease (1/6 PD). BOR within PDTCs was partial remission (PR 2/2). The median progression-free survival was 17.75 months for all patients, and 16.5 months for ATCs, with treatment durations ranging from 1 to 40 months (1, 4, 11, 15, 19, 25, 27, and 40 months). Grade III/IV toxicities developed in 4 of 8 patients, requiring dose reduction/discontinuation of lenvatinib. The median OS was 18.5 months, with three ATC patients being still alive without relapse (40, 27, and 19 months) despite metastatic disease at the time of treatment initiation (UICC and stage IVC). All patients with long-term (>2 years) or complete responses (CRs) had either increased TMB or a PD-L1 TPS >50%. Conclusions: Our results implicate that the combination of lenvatinib and pembrolizumab might be safe and effective in patients with ATC/PDTC and can result in complete and long-term remissions. The combination treatment is now being systematically examined in a phase II clinical trial (Anaplastic Thyroid Carcinoma Lenvatinib Pembrolizumab [ATLEP]) in ATC/PDTC patients.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Dierks C, Seufert J, Aumann K, et al. Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma. Thyroid. 2021. PMID: 33509020. doi:10.1089/thy.2020.0322

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。